188 results on '"Chaker, Adam M."'
Search Results
2. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
3. Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP): Recommendations by German allergy and ORL societies AeDA and DGHNO for dupilumab, omalizumab, and mepolizumab
4. Mild COVID-19 imprints a long-term inflammatory eicosanoid- and chemokine memory in monocyte-derived macrophages
5. Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism
6. Reopening the Bavarian State Opera Safely: Hygiene Strategies and Incidence of COVID-19 in Artistic Staff During Theater Season 2020/2021
7. Extracellular vesicle miRNAs drive aberrant macrophage responses in NSAID‐exacerbated respiratory disease.
8. Endoskopisches Scoring von Nasenpolypen
9. Future directions of Allergen Immunotherapy (AIT) for allergic rhinitis: an experts’ perspective
10. Correction to: Mild COVID-19 imprints a long-term inflammatory eicosanoid- and chemokine memory in monocyte-derived macrophages
11. Treatment considerations for cervical and cervicothoracic spondylodiscitis associated with esophageal fistula due to cancer history or accidental injury: a 9-patient case series
12. Flow-Based CL-SMIA for the Quantification of Protein Biomarkers from Nasal Secretions in Comparison with Sandwich ELISA
13. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti–IL-4: A randomized controlled trial
14. Diagnosis and treatment of Hymenoptera venom allergy
15. Genome-Wide Gene Expression Analysis Reveals Unique Genes Signatures of Epithelial Reorganization in Primary Airway Epithelium Induced by Type-I, -II and -III Interferons
16. AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
17. Dokumentation von Biologika-Therapien bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP): Dupilumab, Omalizumab und Mepolizumab
18. Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP
19. Schwere allergische Reaktionen nach COVID-19-Impfung mit dem Impfstoff von Pfizer/BioNTech in Großbritannien und USA
20. Macrophages acquire a TNF-dependent inflammatory memory in allergic asthma
21. Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism
22. Individualisierte, personalisierte, stratifizierte Medizin: eine Herausforderung für die Allergologie in der HNO?
23. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count
24. Macrophages acquire a TNF-dependent inflammatory memory in allergic asthma
25. TGF-β1 Drives Inflammatory Th Cell But Not Treg Cell Compartment Upon Allergen Exposure
26. Epidemiologie, Krankheitslast und gesundheitsökonomische Aspekte
27. Minderung der Regressgefahr beim Einsatz von Biologika gegen CRSwNP
28. Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
29. White Paper Erdnussallergie - Teil 1: Epidemiologie, Burden of Disease, gesundheitsökonomische Aspekte
30. TGF-β1 Drives Inflammatory Th Cell But Not Treg Cell Compartment Upon Allergen Exposure
31. Reopening the Bavarian State Opera Safely: Hygiene Strategies and Incidence of COVID-19 in Artistic Staff During Theater Season 2020/2021
32. Sputum microRNA‐screening reveals Prostaglandin EP3 receptor as selective target in allergen‐specific immunotherapy
33. Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem
34. Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic – An EAACI Position Paper
35. TGF-β1 drives Th9 but not Treg cells upon allergen exposure
36. Early Reduction of SARS-CoV-2 Replication in Bronchial Epithelium by Kinin B2 Receptor Antagonism
37. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.
38. An exhausted phenotype of TH2 cells is primed by allergen exposure, but not reinforced by allergen‐specific immunotherapy
39. Das europäische Curriculum für die Zusatzbezeichnung Allergologie
40. Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases
41. Allergen‐specific immunotherapy induces the suppressive secretoglobin 1A1 in cells of the lower airways
42. Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper
43. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie
44. Allergen immunotherapy in the current COVID-19 pandemic - A position paper of the AeDA, ARIA, EAACI, DGAKI and GPA
45. Therapy of allergic rhinitis in routine care: evidence-based benefit assessment of freely combined use of various active ingredients: A position paper of the Medical Association of German Allergists (AEDA) in cooperation with the ENT section of the European Academy of Allergy and Clinical Immunology (EAACI), the German ARIA (Allergic Rhinitis and its Impact on Asthma) Group and the Working Group Clinical Immunology, Allergology and Environmental Medicine of the German Society for Otorhinolaryngology, Head and Neck Surgery (DGHNO-KHC)
46. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)
47. Allergy Therapy and Allergy Immunotherapy in Childhood
48. Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement
49. Biologics in Rhinology – Forthcoming Personalized Concepts: the Future Starts Today
50. G-BA attestiert Dupilumab beträchtlichen Zusatznutzen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.